169 related articles for article (PubMed ID: 19303900)
1. GABAB receptors as drug targets to treat gastroesophageal reflux disease.
Lehmann A
Pharmacol Ther; 2009 Jun; 122(3):239-45. PubMed ID: 19303900
[TBL] [Abstract][Full Text] [Related]
2. Novel treatments of GERD: focus on the lower esophageal sphincter.
Lehmann A
Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():103-10. PubMed ID: 18924449
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
Alstermark C; Amin K; Dinn SR; Elebring T; Fjellström O; Fitzpatrick K; Geiss WB; Gottfries J; Guzzo PR; Harding JP; Holmén A; Kothare M; Lehmann A; Mattsson JP; Nilsson K; Sundén G; Swanson M; von Unge S; Woo AM; Wyle MJ; Zheng X
J Med Chem; 2008 Jul; 51(14):4315-20. PubMed ID: 18578471
[TBL] [Abstract][Full Text] [Related]
4. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
Beaumont H; Boeckxstaens GE
Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
[TBL] [Abstract][Full Text] [Related]
5. Treatment of gastro-esophageal reflux disease: the new kids to block.
Blondeau K
Neurogastroenterol Motil; 2010 Aug; 22(8):836-40. PubMed ID: 20663054
[TBL] [Abstract][Full Text] [Related]
6. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.
Johnson DA; Levy BH
Expert Opin Pharmacother; 2010 Jun; 11(9):1541-8. PubMed ID: 20450445
[TBL] [Abstract][Full Text] [Related]
7. Reflux inhibitors: a new approach for GERD?
Boeckxstaens GE
Curr Opin Pharmacol; 2008 Dec; 8(6):685-9. PubMed ID: 18771751
[TBL] [Abstract][Full Text] [Related]
8. GABAB receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease.
Lehmann A; Jensen JM; Boeckxstaens GE
Adv Pharmacol; 2010; 58():287-313. PubMed ID: 20655487
[TBL] [Abstract][Full Text] [Related]
9. Lesogaberan, a GABA(B) agonist for the potential treatment of gastroesophageal reflux disease.
Bredenoord AJ
IDrugs; 2009 Sep; 12(9):576-84. PubMed ID: 19697277
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for gastroesophageal reflux disease.
Boeckxstaens GE
Expert Opin Emerg Drugs; 2009 Sep; 14(3):481-91. PubMed ID: 19650746
[TBL] [Abstract][Full Text] [Related]
11. The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs.
Brändén L; Fredriksson A; Harring E; Jensen J; Lehmann A
Eur J Pharmacol; 2010 May; 634(1-3):138-41. PubMed ID: 20176012
[TBL] [Abstract][Full Text] [Related]
12. The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study.
Beaumont H; Smout A; Aanen M; Rydholm H; Lei A; Lehmann A; Ruth M; Boeckxstaens G
Aliment Pharmacol Ther; 2009 Nov; 30(9):937-46. PubMed ID: 19650825
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological targets in gastro-oesophageal reflux disease.
Piche T; Galmiche JP
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):333-41. PubMed ID: 16364047
[TBL] [Abstract][Full Text] [Related]
14. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease.
Tack J
Curr Opin Gastroenterol; 2005 Jul; 21(4):454-60. PubMed ID: 15930988
[TBL] [Abstract][Full Text] [Related]
15. Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'.
Boeckxstaens GE; Denison H; Jensen JM; Lehmann A; Ruth M
Curr Opin Pharmacol; 2011 Dec; 11(6):630-3. PubMed ID: 22036168
[TBL] [Abstract][Full Text] [Related]
16. Medical treatment of GORD. Emerging therapeutic targets and concepts.
Zerbib F
Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):937-46. PubMed ID: 21126705
[TBL] [Abstract][Full Text] [Related]
17. New pharmacological agents for the treatment of gastroesophageal reflux disease.
Vakil N
Rev Gastroenterol Disord; 2008; 8(2):117-22. PubMed ID: 18641594
[TBL] [Abstract][Full Text] [Related]
18. New horizons in the medical treatment of gastro-oesophageal reflux disease.
Dekel R; Fass R
Minerva Gastroenterol Dietol; 2003 Dec; 49(4):277-87. PubMed ID: 16484967
[TBL] [Abstract][Full Text] [Related]
19. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
Miyamoto M; Haruma K; Kuwabara M; Nagano M; Okamoto T; Tanaka M
J Gastroenterol Hepatol; 2007 May; 22(5):639-44. PubMed ID: 17444849
[TBL] [Abstract][Full Text] [Related]
20. (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.
Lehmann A; Antonsson M; Holmberg AA; Blackshaw LA; Brändén L; Bräuner-Osborne H; Christiansen B; Dent J; Elebring T; Jacobson BM; Jensen J; Mattsson JP; Nilsson K; Oja SS; Page AJ; Saransaari P; von Unge S
J Pharmacol Exp Ther; 2009 Nov; 331(2):504-12. PubMed ID: 19648470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
